Promising Phase 2 Results for Myasthenia Gravis Med Promising Phase 2 Results for Myasthenia Gravis Med

Intravenous nipocalimab provides clinical benefits for patients with generalized myasthenia gravis, an IgG autoantibody-mediated disease characterized by muscle weakness.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Neurology & Neurosurgery Source Type: news